Indolent systemic mastocytosis
MONDO:0020331Indolent systemic mastocytosis (ISM) is a benign form of systemic mastocytosis (SM) characterized by an abnormal proliferation of mast cells either only in bone marrow or in numerous tissues.
Also known as: ISM, indolent systemic mastocytosis (morphologic abnormality), ism
1854 clinical trials for this condition and its sub-types, 8 tagged with Indolent systemic mastocytosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Indolent systemic mastocytosis
-
Smouldering systemic mastocytosis 3 trials
-
Isolated bone marrow mastocytosis 2 trials
-
New drug aims to ease daily misery of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to ease symptoms of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether avapritinib, a targeted drug taken as a tablet, can reduce symptoms in people with indolent systemic mastocytosis whose symptoms are not well controlled by standard care. About 251 participants will receive either avapritinib or a placebo, and all…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC